Literature DB >> 1547169

Clinical assessment of fetal electrocardiogram monitoring in labour.

K W Murphy1, V Russell, P Johnson, J Valente.   

Abstract

OBJECTIVE: To assess the potential clinical value of fetal electrocardiographic (ECG) monitoring in labour.
DESIGN: Descriptive study of the use of ECG waveform analysis during labour and its correlation with other indices of fetal and neonatal well-being.
SETTING: Teaching hospital in Oxford.
SUBJECTS: 86 high risk pregnancies. MAIN OUTCOME MEASURES: Suitability of ST Segment Analyser (Cinventa, Sweden) for clinical use; relation between the T/QRS ratio during labour (an index of ST segment and T wave elevation) and intrapartum cardiotocography, umbilical artery pH at birth and Apgar scores; T/QRS ratio trends in labour.
RESULTS: The system was robust and user-friendly. No statistically significant relation was found between T/QRS ratios in labour and FHR abnormalities in the cardiotocograph. There was a weak relation between T/QRS ratios and umbilical artery acidosis: at a cervical dilatation of 4 cm, the Spearman rank correlation of the mean T/QRS ratio with umbilical artery actual base deficit was r = -0.31, 0.05 greater than P greater than 0.01. The correlation of T/QRS with the umbilical artery pH was not statistically significant, although a trend was present (Spearman rank: r = -0.26, P greater than 0.05). Correlation of the T/QRS ratio with Apgar scores at 1 and at 5 min was not statistically significant. Only 3 of 16 infants with an Apgar score of less than 7 at 1 min had a mean T/QRS ratio above 0.25 at any time during labour.
CONCLUSION: Further research is necessary before a decision can be made whether this new method of fetal monitoring should be introduced into clinical practice.

Entities:  

Mesh:

Year:  1992        PMID: 1547169     DOI: 10.1111/j.1471-0528.1992.tb14388.x

Source DB:  PubMed          Journal:  Br J Obstet Gynaecol        ISSN: 0306-5456


  1 in total

1. 

Authors:  F Béguin
Journal:  Arch Gynecol Obstet       Date:  1995-12       Impact factor: 2.344

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.